Press release
Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Growth
ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.
Access Report Overview: www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis
Insights on pipeline analysis
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.
Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.
Explore Report Sample at: www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample
Major companies collaborate for the development of ER+ breast cancer pipeline
The research finds that different companies have collaborated for the development of ER+ breast cancer. In May 2015, Tesaro, Inc entered in a collaboration with Merck & Co. to evaluate the combination of Tesaro’s Niraparib plus Merck’s anti-PD1 therapy, Keytruda (pembrolizumab), in a Phase 1/2 clinical trial. Also, in January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.
Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com
347, 5th Ave. #1402
New York City, NY - 10016
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Growth here
News-ID: 476708 • Views: …
More Releases from P&S Market Research- Pharmaceuticals
Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therap …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants…
Global Esophageal Cancer Therapeutics Market Analysis, Development and Demand Fo …
Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.
Explore…
Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Developm …
The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth.
Explore Report at: www.psmarketresearch.com/market-analysis/pancreatic-cancer-therapeutics-market
Cancer instigates uncountable growth of cells due to some abnormalities…
Serine/Threonine-Protein Kinase Inhibitors Pipeline Analysis, 2016
Serine/threonine-protein kinases (EC 2.7.11.1) are enzyme or protein that has hydroxyl (OH) group in the side chain. Phosphorylation in serine or threonine residues may cause changes in the function of the target protein. Those drugs/ligands that inhibit phosphorylating activity of these kinases are called serine/threonine protein kinases inhibitors. Serine/threonine kinase receptors are a family of transmembrane receptors containing intracellular serine/threonine kinase domains that respond to a few cytokines including the…
More Releases for ER+
ER+/HER2- Breast Cancer Market Insights and Future Outlook
Introduction
Estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer is the most common molecular subtype of breast cancer, accounting for nearly 70% of all breast cancer diagnoses worldwide. This classification is defined by tumors that express estrogen receptors (ER) but lack human epidermal growth factor receptor 2 (HER2) amplification. The subtype's dominance in global oncology has positioned it as the central focus for therapeutic innovation, guidelines development, and precision medicine strategies.
Historically managed with…
Er YAG Laser Market Outlook and Future Projections for 2030
An Er:YAG laser (erbium-doped yttrium aluminum garnet) is a type of solid-state laser commonly used in medical and cosmetic procedures. It emits light at a wavelength of 2940 nm, which is highly absorbed by water, making it effective for precise tissue ablation and resurfacing. This laser is popular in dermatology and dentistry for its ability to gently remove layers of skin or tissue with minimal thermal damage and quick healing.
The…
Optical Brightener ER-I and ER-II Market Size Unveiled: Trends and Projections
The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep into the drivers, restraints,…
Optical Brightener ER-I and ER-II Market by Key Players,Competitive landscape an …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is analyzed in quite some detail in the report with a strong focus on the competitive landscape, segmentation, market dynamics, and regional market expansion. The report includes a thorough assessment of the business of key players operating in the global Optical Brightener ER-I and ER-II market. With deeper qualitative and quantitative analysis of the global Optical Brightener ER-I and…
Optical Brightener ER-I and ER-II Market Trends, Regional Overview, Leading Comp …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep…
ER Wagner adding 600-ton Servo Punch Press
Milwaukee-based ER Wagner announced it will have a new 600-ton Servo Punch Press available for production in late 2017, greatly increasing ER Wagner’s metal stamping capabilities.
The Nidec Minster Corporation machine, which will be a part of ER Wagner’s new 157,000-square-foot corporate headquarters and state of the art manufacturing facility currently under construction in the Village of Menomonee Falls, Wis., is latest technology in metal stamping, giving the company the ability…
